Business Model & Revenue
Cue Biopharma, Inc. (NASDAQ: CUE) is a Boston-based clinical-stage biopharmaceutical company founded in 2014. The company develops a novel class of injectable biologics called "Cue Biologics" — fusion proteins engineered to selectively engage and modulate specific T cell populations in vivo for targeted treatment of cancer and autoimmune diseases.
The platform technology: Cue's biologics are designed to deliver antigen-specific signals directly to T cells, activating or suppressing immune responses with high specificity. This approach aims to overcome the limitations of traditional immunotherapies (checkpoint inhibitors, CAR-T) by targeting specific antigens without broad immune activation.
Key programs:
- CUE-102: Lead oncology program targeting HPV+ cancers, partnered with Bristol Myers Squibb. Phase 2b initiation pending review.
- CUE-401: Preclinical oncology program. Generated $7.5M milestone payment (May 2026).
- CUE-501: Preclinical program (autoimmune or oncology). Part of the milestone payment trigger.
Revenue model: 100% milestone payments and collaboration fees from pharma partnerships. Zero product revenue. No commercial products. The company is entirely dependent on partnership economics and future clinical success to generate returns.
The company appointed an interim CEO on March 27, 2026. Cue Biopharma has approximately 40-50 employees and has been public since 2019.
Financial Highlights
Income Statement
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $27.5M | $9.3M | $5.5M | $1.2M | $14.9M |
| Revenue Growth | 195.8% | 69.2% | 341.0% | -91.7% | 373.7% |
| Gross Profit | $27.5M | $9.3M | $5.5M | $1.2M | $14.9M |
| Gross Margin | 100% | 100% | 100% | 100% | 100% |
| Operating Income | ($26.6)M | ($41.5)M | ($52.2)M | ($53.2)M | ($43.7)M |
| Net Income | ($26.6)M | ($40.7)M | ($50.7)M | ($53.0)M | ($44.2)M |
| EPS | ($8.40) | ($21.60) | ($33.30) | ($44.70) | ($42.30) |
| R&D | $37.7M | $36.3M | $40.8M | $38.6M | $41.4M |
| SG&A | $16.2M | $14.6M | $16.7M | $16.2M | $17.3M |
| FCF | ($21.9)M | ($36.4)M | ($40.0)M | ($42.0)M | ($39.8)M |
Key Metrics
| Metric | Value |
|---|---|
| Market Cap (post-surge) | ~$92M |
| Shares Outstanding | 3.22M |
| Share Dilution (YoY) | +68% |
| Price/Revenue (FY2025) | 3.3x |
| Enterprise Value | ~$50-70M (net cash positive post-financing) |
| 52-Week Range | N/A |
| Pre-surge Price | ~$14.75 |
| New Financing | $30M (private placement) |
| Milestone Received | $7.5M (May 1) |
Revenue Breakdown (100% Milestones)
| Year | Revenue | Source |
|---|---|---|
| FY2025 | $27.5M | BMS collaboration milestones |
| FY2024 | $9.3M | BMS collaboration milestones |
| FY2023 | $5.5M | BMS collaboration milestones |
| FY2022 | $1.2M | BMS collaboration milestones |
| FY2021 | $14.9M | BMS upfront + milestones |
100% gross margin confirms zero COGS — this is a pure R&D company funded by pharma partnership economics.
Cash Flow
| Component | FY2025 |
|---|---|
| FCF | ($21.9)M |
| New Financing | $30M |
| Milestone Received | $7.5M |
| Total Inflow | $37.5M |
| Runway Extension | ~17-20 months |
Note: FY2021's $14.9M revenue spike reflects the initial BMS partnership upfront payment.
Competitive Landscape
Cue Biopharma operates in the immuno-oncology space, specifically in selective T-cell modulation:
-
Bristol Myers Squibb (BMY): Cue's partner for CUE-102. BMS is an oncology powerhouse with Opdivo, Yervoy, and CAR-T therapies. The partnership validates Cue's technology but also means BMS controls key program decisions.
-
Moderna (MRNA), BioNTech (BNTX): Developing individualized cancer vaccines and mRNA-based immunotherapies. Different approach but competing for the same immuno-oncology investment dollars.
-
Adaptimmune (ADAP), Immatics (IMTX): TCR-engineered T-cell therapies for solid tumors. More advanced clinically than Cue's approach.
-
Gilead (GILD) / Kite Pharma: CAR-T market leader. Different technology but same broad category of cell-based cancer immunotherapy.
-
AnaptysBio (ANAB), Xencor (XENC): Developing selective immunomodulators. Nearest comparable technology approach to Cue's platform.
Cue's differentiation: The injectable biologic approach (vs. cell therapies like CAR-T) could be significantly cheaper and more scalable if it works. No manufacturing complexity, no patient-specific engineering, no hospital infusion requirements. But it's also unproven — the key question is whether Cue's selective T-cell modulation can achieve meaningful clinical responses in solid tumors.
The partnership premium: Being partnered with BMS gives Cue credibility, funding, and regulatory expertise. But it also means Cue gives up economics (milestones and royalties rather than full commercial rights) and cedes program control to a larger partner.
Catalysts
-
$30M private placement close (immediate): Extends cash runway. Removes near-term existential risk. Already announced — driving today's surge.
-
$7.5M milestone payment received (May 1): Validates CUE-401/CUE-501 preclinical progress. Already received.
-
CUE-102 Phase 2b initiation decision: If BMS/Cue decide to advance into Phase 2b, it would be a major catalyst. Timing uncertain.
-
CUE-102 clinical data readout: Any Phase 2 data would be the most significant potential catalyst. Would determine the program's commercial viability.
-
Additional partnership/milestone payments: BMS or new partners could trigger further milestones as programs advance.
-
Permanent CEO appointment: Resolving the interim CEO situation would provide leadership clarity.
Key Risks
- Zero product revenue. All $27.5M FY2025 revenue comes from BMS collaboration milestones, not product sales.
- $26.6M annual net loss. The company cannot sustain itself without continued financing or milestone payments.
- 68% share dilution YoY (1.89M → 3.22M shares). Private placement will likely dilute further.
- CUE-102 Phase 2b has not been initiated. Key decision pending — program may not advance.
- CUE-401 and CUE-501 are preclinical. Years from potential clinical data.
- Interim CEO since March 27, 2026. Leadership uncertainty during a critical period.
- R&D spend of $37.7M/year with no products. Every dollar is a bet on future clinical success.
- T-cell engager technology is novel but unproven at scale. Clinical-stage biotech binary risk — most programs fail.
- $92M market cap prices in clinical success. Downside risk is significant if programs stumble.
- BMS partnership economics are favorable but create dependency. BMS has leverage over program decisions.
Our Thesis
The bull case: Cue Biopharma has a legitimate partnership with Bristol Myers Squibb, one of the world's largest oncology companies. BMS doesn't partner lightly — the CUE-102 T-cell engager technology must have shown compelling preclinical/clinical data to attract their involvement. Revenue growth from $9.3M to $27.5M (196% YoY) reflects milestone economics as programs advance. The $30M financing + $7.5M milestone provides $37.5M in immediate liquidity, extending runway to potentially 12-18 months. If CUE-102 Phase 2b data reads out positively, this stock could re-rate significantly — BMS partnership economics could generate hundreds of millions in future milestones and royalties. The technology platform (selective T-cell modulation) is genuinely novel in the immuno-oncology space.
The bear case: $92M market cap for a company with $27.5M in non-product revenue and $26.6M in losses. Revenue is entirely milestone-driven — if the BMS partnership stalls or programs fail, revenue drops to zero. The company has been diluting aggressively (68% share growth YoY) and will likely dilute further to fund operations. R&D spend of $37.7M/year on 3.22M shares means $11.70/share in annual R&D burn alone. The CUE-102 program is still early — Phase 2b has not been initiated yet ("may initiate after review"). CUE-401 and CUE-501 are preclinical. There is no near-term path to commercialization for any program. The interim CEO (since March 27) adds leadership uncertainty. Clinical-stage biotech is binary — most fail.
Neutral because the financing removes the existential risk that was the biggest bear case, but the company remains pre-revenue, cash-burning, and dilutive. The BMS partnership is the real asset — everything else is hope.
Get reports like this delivered free
New small-cap research every week. No paywall, no fluff.